



Rasagiline Mylan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
N/0012	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	22/02/2023		PL	
N/0011	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	18/10/2022		PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



IB/0010	B.II.b.5.f - Change to in-process tests or limits applied during the manufacture of the finished product - Addition or replacement of an in-process test as a result of a safety or quality issue	22/03/2022	n/a		
T/0009	Transfer of Marketing Authorisation	24/09/2021	19/10/2021	SmPC, Labelling and PL	
IB/0008/G	This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.I.z - Quality change - Active substance - Other variation	08/10/2021	n/a		
IB/0007	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by	02/07/2021	19/10/2021	SmPC and PL	To update section 4.4 of the SmPC and section 2 and 4 of the PL to align adverse effects based on the Brand Leader's text.

	the MAH				
R/0006	Renewal of the marketing authorisation.	17/09/2020	20/11/2020	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rasagiline Mylan in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/04/2020	20/11/2020	PL	
IA/0005/G	This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites	10/04/2020	n/a		
N/0003	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	24/01/2019	20/11/2020	Labelling and PL	
IA/0002	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	15/09/2016	n/a		
IAIN/0001/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.	18/05/2016	08/05/2017	SmPC, Labelling and PL	

tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes
B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes